This quarterly report series examines the current management of unresectable/metastatic malignant melanoma in the United States from the perspective of medical oncologists and explores trends in treatment practices. It enables a greater understanding of medical practice patterns in unresectable/metastatic malignant melanoma, segmented by BRAF-mutational status; of physicians’ perceptions of drug brands, including recently launched BRAF-targeted therapies and anti-PD-1 immunotherapies, and of specific product attributes; and of the impact of sales and brand messaging efforts.

Questions Answered in This Report:

  • Assess current and anticipated prescribing of targeted therapies and new immunotherapies for unresectable or metastatic malignant melanoma. How does prescribing of currently available therapies differ by BRAF mutational status and by line of therapy? How is prescribing anticipated to change over the next six months?

  • Assess how the importance and performance of various attributes (e.g., efficacy, safety, dosing) differ among covered products. How important, for example, is providing durable response or improving quality of life, according to surveyed medical oncologists? How do new immune checkpoint inhibitors, such as Bristol-Myers Squibb’s Yervoy and Opdivo and Merck & Co.’s Keytruda, perform on these attributes? What are the hidden opportunities and obstacles for increasing drug use for manufacturers?

  • Assess and compare sales representatives’ contact frequency and performance, as well as physician message recall of products. How many times, on average, in the past six months has a sales representative visited physicians for the various current therapies? What percentages of physicians were visited in the past month for each product, and what messages were recalled by brand?

  • Understand medical oncologists’ perception of therapies for late-phase malignant melanoma, including awareness of and familiarity with products in clinical development. The report covers 11 products in development. Which drug characteristics do surveyed medical oncologists perceive as the most important when treating unresectable or metastatic malignant melanoma? How do surveyed medical oncologists rank future malignant melanoma treatments (e.g., PD-1/PD-L1 inhibitors, BRAF inhibitors, therapeutic vaccines, oncolytic immunotherapies)?

Scope:

Markets covered: United States.

Primary research: 102 medical oncologists.

Indication coverage: Unresectable or metastatic malignant melanoma.

Emerging therapies covered: Phase I: 1 drug; Phase II: 3 drugs; Phase III: 7 drugs; registered: 14 drugs.

Author(s): Michalina Jenkins, M.Sc., Ph.D.

Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details